Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Buy
75
ERFSF Quote, Financials, Valuation and Earnings
Last price:
$78.80
Seasonality move
:
9.75%
Day range:
$78.80 - $81.32
52-week range:
$46.37 - $83.02
Dividend yield:
1.55%
P/E ratio:
29.91x
P/S ratio:
1.94x
P/B ratio:
64.77x
Volume:
67.9K
Avg. volume:
4.5K
1-year change:
57.69%
Market cap:
$13.9B
Revenue:
$7.5B
EPS (TTM):
$2.55
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
-- | -- | -- | -- | -- |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
ALVO
Alvotech
|
$141.5M | $0.03 | 9.08% | -98.04% | $22.17 |
|
AUNA
Auna SA
|
$337.1M | $0.21 | 11.49% | 111.39% | $8.75 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
PROCF
Sofgen Pharma SA
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
$78.80 | -- | $13.9B | 29.91x | $0.68 | 1.55% | 1.94x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
ALVO
Alvotech
|
$4.64 | $22.17 | $1.4B | 20.15x | $0.00 | 0% | 2.56x |
|
AUNA
Auna SA
|
$4.88 | $8.75 | $361.2M | 7.07x | $0.00 | 0% | 0.31x |
|
CVM
CEL-SCI Corp.
|
$5.48 | $42.50 | $16.6M | -- | $0.00 | 0% | -- |
|
PROCF
Sofgen Pharma SA
|
$0.07 | -- | $161.3M | -- | $0.00 | 0% | 0.02x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
43.41% | -0.264 | -- | 1.08x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
ALVO
Alvotech
|
115.99% | 3.133 | 50.24% | 0.54x |
|
AUNA
Auna SA
|
68.8% | 1.277 | 194.28% | 0.70x |
|
CVM
CEL-SCI Corp.
|
37.03% | 0.660 | 33.61% | 2.14x |
|
PROCF
Sofgen Pharma SA
|
-- | 610.431 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ERFSF
Eurofins Scientific SE
|
-- | -- | 5.27% | 8.55% | -- | -- |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
ALVO
Alvotech
|
$78.7M | $1.2M | 7.33% | -- | 1.05% | -$84M |
|
AUNA
Auna SA
|
$118.6M | $43.8M | 3.64% | 11.53% | 13.85% | $25.8M |
|
CVM
CEL-SCI Corp.
|
-$960.8K | -$6M | -117.93% | -230.36% | -- | -$4.7M |
|
PROCF
Sofgen Pharma SA
|
-- | -- | -- | -- | -- | -- |
Eurofins Scientific SE vs. Competitors
-
Which has Higher Returns ERFSF or AIM?
AIM ImmunoTech has a net margin of -- compared to Eurofins Scientific SE's net margin of -10571.43%. Eurofins Scientific SE's return on equity of 8.55% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About ERFSF or AIM?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Eurofins Scientific SE, analysts believe AIM ImmunoTech is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 AIMAIM ImmunoTech1 0 0 -
Is ERFSF or AIM More Risky?
Eurofins Scientific SE has a beta of 0.631, which suggesting that the stock is 36.887% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock ERFSF or AIM?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.55%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or AIM?
Eurofins Scientific SE quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Eurofins Scientific SE's net income of -- is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 29.91x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.94x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.94x 29.91x -- -- AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns ERFSF or ALVO?
Alvotech has a net margin of -- compared to Eurofins Scientific SE's net margin of -4.62%. Eurofins Scientific SE's return on equity of 8.55% beat Alvotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B ALVOAlvotech69.22% -$0.02 $1.1B -
What do Analysts Say About ERFSF or ALVO?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Alvotech has an analysts' consensus of $22.17 which suggests that it could grow by 377.73%. Given that Alvotech has higher upside potential than Eurofins Scientific SE, analysts believe Alvotech is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 ALVOAlvotech3 1 0 -
Is ERFSF or ALVO More Risky?
Eurofins Scientific SE has a beta of 0.631, which suggesting that the stock is 36.887% less volatile than S&P 500. In comparison Alvotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ERFSF or ALVO?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.55%. Alvotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. Alvotech pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or ALVO?
Eurofins Scientific SE quarterly revenues are --, which are smaller than Alvotech quarterly revenues of $113.7M. Eurofins Scientific SE's net income of -- is lower than Alvotech's net income of -$5.3M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 29.91x while Alvotech's PE ratio is 20.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.94x versus 2.56x for Alvotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.94x 29.91x -- -- ALVOAlvotech2.56x 20.15x $113.7M -$5.3M
-
Which has Higher Returns ERFSF or AUNA?
Auna SA has a net margin of -- compared to Eurofins Scientific SE's net margin of 4.74%. Eurofins Scientific SE's return on equity of 8.55% beat Auna SA's return on equity of 11.53%.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B AUNAAuna SA37.52% $0.18 $1.6B -
What do Analysts Say About ERFSF or AUNA?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Auna SA has an analysts' consensus of $8.75 which suggests that it could grow by 79.3%. Given that Auna SA has higher upside potential than Eurofins Scientific SE, analysts believe Auna SA is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 AUNAAuna SA2 2 0 -
Is ERFSF or AUNA More Risky?
Eurofins Scientific SE has a beta of 0.631, which suggesting that the stock is 36.887% less volatile than S&P 500. In comparison Auna SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ERFSF or AUNA?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.55%. Auna SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. Auna SA pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or AUNA?
Eurofins Scientific SE quarterly revenues are --, which are smaller than Auna SA quarterly revenues of $316.1M. Eurofins Scientific SE's net income of -- is lower than Auna SA's net income of $15M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 29.91x while Auna SA's PE ratio is 7.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.94x versus 0.31x for Auna SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.94x 29.91x -- -- AUNAAuna SA0.31x 7.07x $316.1M $15M
-
Which has Higher Returns ERFSF or CVM?
CEL-SCI Corp. has a net margin of -- compared to Eurofins Scientific SE's net margin of --. Eurofins Scientific SE's return on equity of 8.55% beat CEL-SCI Corp.'s return on equity of -230.36%.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B CVMCEL-SCI Corp.-- -$0.76 $25.3M -
What do Analysts Say About ERFSF or CVM?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 675.55%. Given that CEL-SCI Corp. has higher upside potential than Eurofins Scientific SE, analysts believe CEL-SCI Corp. is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 CVMCEL-SCI Corp.1 0 0 -
Is ERFSF or CVM More Risky?
Eurofins Scientific SE has a beta of 0.631, which suggesting that the stock is 36.887% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.183%.
-
Which is a Better Dividend Stock ERFSF or CVM?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.55%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or CVM?
Eurofins Scientific SE quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Eurofins Scientific SE's net income of -- is lower than CEL-SCI Corp.'s net income of -$6.1M. Notably, Eurofins Scientific SE's price-to-earnings ratio is 29.91x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.94x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.94x 29.91x -- -- CVMCEL-SCI Corp.-- -- -- -$6.1M
-
Which has Higher Returns ERFSF or PROCF?
Sofgen Pharma SA has a net margin of -- compared to Eurofins Scientific SE's net margin of --. Eurofins Scientific SE's return on equity of 8.55% beat Sofgen Pharma SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ERFSFEurofins Scientific SE-- -- $9.6B PROCFSofgen Pharma SA-- -- -- -
What do Analysts Say About ERFSF or PROCF?
Eurofins Scientific SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Sofgen Pharma SA has an analysts' consensus of -- which suggests that it could grow by 7042.86%. Given that Sofgen Pharma SA has higher upside potential than Eurofins Scientific SE, analysts believe Sofgen Pharma SA is more attractive than Eurofins Scientific SE.
Company Buy Ratings Hold Ratings Sell Ratings ERFSFEurofins Scientific SE0 0 0 PROCFSofgen Pharma SA0 0 0 -
Is ERFSF or PROCF More Risky?
Eurofins Scientific SE has a beta of 0.631, which suggesting that the stock is 36.887% less volatile than S&P 500. In comparison Sofgen Pharma SA has a beta of 62.945, suggesting its more volatile than the S&P 500 by 6194.533%.
-
Which is a Better Dividend Stock ERFSF or PROCF?
Eurofins Scientific SE has a quarterly dividend of $0.68 per share corresponding to a yield of 1.55%. Sofgen Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eurofins Scientific SE pays 28.14% of its earnings as a dividend. Sofgen Pharma SA pays out -- of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ERFSF or PROCF?
Eurofins Scientific SE quarterly revenues are --, which are smaller than Sofgen Pharma SA quarterly revenues of --. Eurofins Scientific SE's net income of -- is lower than Sofgen Pharma SA's net income of --. Notably, Eurofins Scientific SE's price-to-earnings ratio is 29.91x while Sofgen Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eurofins Scientific SE is 1.94x versus 0.02x for Sofgen Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERFSFEurofins Scientific SE1.94x 29.91x -- -- PROCFSofgen Pharma SA0.02x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
